<DOC>
	<DOC>NCT02013310</DOC>
	<brief_summary>This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment (AAMI)</brief_summary>
	<brief_title>HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)</brief_title>
	<detailed_description />
	<mesh_term>Memory Disorders</mesh_term>
	<criteria>Main Complaints of memory loss in everyday life Performance at least one standard deviation below the mean established for young adults on standardized memory tests Absence of dementia Intact global intellectual function Main Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease Evidence of dementia Evidence of psychiatric or neurological disorder that could influence cognition or contributed to the subject's memory loss Use of any drugs that could influence cognition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>